Harbour BioMed nets $75M in Series B+ as first global trial gets underway

Harbour BioMed nets $75M in Series B+ as first global trial gets underway

Submitted by admin on March 12, 2020 - 10:50am
Source: 
Endpoints
News Tags: 
Harbor BioMed
Shanghai
Headline: 
Harbour BioMed nets $75M in Series B+ as first global trial gets underway
snippet: 

Nearly two years after drawing an $85 million Series B, Shanghai-based Harbour BioMed has announced a new large funding round.

Do Not Allow Advertisers to Use My Personal information